(CercleFinance.com) – Bastide publishes a half-year turnover of 265 ME as of December 31, an organic increase of 5.7% compared to the same period a year earlier (and +6.2% as published).
Activity remained very dynamic in the second quarter with an acceleration in organic growth to +6.1%, after +5.2% in the first quarter.
In detail, the more technical activities (Respiratory, Nutrition-Perfusion-Stomatherapy), which now represent 60% of turnover, recorded organic growth of +10.4% in the second quarter, in line with that recorded in the first quarter.
For its part, the ‘Home Support’ activity remains stable in a market which has now normalized after the health crisis.
In this context, the group maintains its 2023/2024 forecasts and targets an annual turnover of around 530 ME (adjusted for the impact linked to the sale of Distrimed and excluding new external growth operations) with an operating margin objective current at least equal to that achieved over the 2022-2023 financial year, i.e. 8.4%,
In addition, the group specifies that debt reduction remains its priority and that the recent sale of Distrimed fully met this objective.
Bastide is still studying possible asset sales which would no longer meet its strategy.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information on BASTIDE LE CONFORT in real time: